lapatinib has been researched along with abemaciclib in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (abemaciclib) | Trials (abemaciclib) | Recent Studies (post-2010) (abemaciclib) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 352 | 43 | 343 |
| Protein | Taxonomy | lapatinib (IC50) | abemaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0734 | |
| Cyclin-K | Homo sapiens (human) | 0.065 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.7586 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.62 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0097 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.7484 | |
| Cyclin-A2 | Homo sapiens (human) | 0.1036 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0048 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.232 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.1847 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0112 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 2.027 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0693 | |
| Cyclin-H | Homo sapiens (human) | 2.6027 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 3.106 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.0168 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.405 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.405 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Ait-Oudhia, S; Franco, YL; Mody, H; Perez, L; Ramakrishnan, V; Vaidya, TR | 1 |
| Hiramoto, M; Hirota, A; Kazama, H; Miyazaki, M; Miyazawa, K; Ogawa, M; Ota, K; Suzuki, S; Takano, N | 1 |
1 review(s) available for lapatinib and abemaciclib
| Article | Year |
|---|---|
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
3 other study(ies) available for lapatinib and abemaciclib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; MAP Kinase Signaling System; Network Pharmacology; Protein Interaction Maps; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2021 |
Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Fingolimod Hydrochloride; Humans; Hydroxychloroquine; Lapatinib; Lysosomes; Pancreatic Neoplasms; Sphingosine 1 Phosphate Receptor Modulators | 2022 |